Skip to content
Cardiovascular healthEvidence review4 min read

Lowering blood pressure reduced new type 2 diabetes, but the effect differs by drug class

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. · Lancet (London, England) · 2021 · Original paper ↗

Key takeaway

Across 19 randomised trials with 145 939 participants, lowering systolic blood pressure by 5 mm Hg reduced new-onset type 2 diabetes by 11% (HR 0.89, 95% CI 0.84-0.95), though drug classes differed: ACE inhibitors and ARBs lowered risk, while beta blockers and thiazide diuretics raised it. The trials were run between 1973 and 2008 and were not designed to test diabetes prevention, so diabetes was not the original main endpoint.

Study design

Evidence review

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Blood pressure lowering is known to prevent complications in people who already have diabetes, but whether it also prevents diabetes is unclear. The authors used participant-level data from major randomised trials to test the effect of lowering blood pressure itself, and the differing effects of five main antihypertensive drug classes, on new-onset type 2 diabetes.

Who and how

Individual participant data meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration, using 22 studies conducted between 1973 and 2008. Trials had to compare a drug class with placebo or another class and have at least 1000 person-years of follow-up per arm; people with diabetes at baseline were excluded. A one-stage meta-analysis (19 trials) used a stratified Cox model for the effect of blood pressure lowering, and a network meta-analysis (22 trials) used logistic regression to compare drug classes. Median follow-up was 4.5 years (IQR 2.0).

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Among 145 939 participants (88 500 men and 57 429 women), 9883 were diagnosed with new-onset type 2 diabetes.
  2. 2
    A 5 mm Hg reduction in systolic blood pressure reduced the risk of type 2 diabetes by 11% (HR 0.89, 95% CI 0.84-0.95).
  3. 3
    Compared with placebo, angiotensin-converting enzyme inhibitors (RR 0.84, 95% CI 0.76-0.93) and angiotensin II receptor blockers (RR 0.84, 95% CI 0.76-0.92) reduced risk.
  4. 4
    Beta blockers (RR 1.48, 95% CI 1.27-1.72) and thiazide diuretics (RR 1.20, 95% CI 1.07-1.35) increased risk, and calcium channel blockers had no material effect (RR 1.02, 95% CI 0.92-1.13).

Limits & uncertainty

  1. 1
    Trials ran from 1973 to 2008 and median follow-up was only 4.5 years, so current practice and long-term effects may differ.
  2. 2
    The trials enrolled people with hypertension or cardiovascular risk and excluded those with diabetes at baseline, so the results do not apply to people with normal blood pressure.
  3. 3
    Drug-class comparisons came from a network meta-analysis, and the abstract does not report how new-onset diabetes was ascertained in each trial.
  4. 4
    The drug differences are attributed by the authors to off-target effects, which this analysis did not test. This reading is based on the abstract only.

What to take from it

For people who need blood pressure treatment, drug choice may matter for later diabetes risk, with ACE inhibitors and ARBs looking most favourable here, but beta blockers and thiazides are still used for good reasons. Do not stop or switch medication because of this finding. Decisions about blood pressure treatment belong with your clinician.

Reading your own data

A home blood pressure cuff, read at the same time of day and posture, lets you and your clinician see whether your average is moving, which is the exposure studied here. Weight and fasting glucose logs can add context for diabetes risk, and trends over weeks matter more than a single reading.

How to read this evidence

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Blood pressure lowering is an established strategy for preventing microvascular and macrovascular complications of diabetes, but its role in the prevention of diabetes itself is unclear. We aimed to examine this question using individual participant data from major randomised controlled trials.

Methods

We performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes. An individual participant data network meta-analysis was used to investigate the differential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 diabetes. Overall, data from 22 studies conducted between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We included all primary and secondary prevention trials that used a specific class or classes of antihypertensive drugs versus placebo or other classes of blood pressure lowering medications that had at least 1000 persons-years of follow-up in each randomly allocated arm. Participants with a known diagnosis of diabetes at baseline and trials conducted in patients with prevalent diabetes were excluded. For the one-stage individual participant data meta-analysis we used stratified Cox proportional hazards model and for the individual participant data network meta-analysis we used logistic regression models to calculate the relative risk (RR) for drug class comparisons.

Findings

145 939 participants (88 500 [60·6%] men and 57 429 [39·4%] women) from 19 randomised controlled trials were included in the one-stage individual participant data meta-analysis. 22 trials were included in the individual participant data network meta-analysis. After a median follow-up of 4·5 years (IQR 2·0), 9883 participants were diagnosed with new-onset type 2 diabetes. Systolic blood pressure reduction by 5 mm Hg reduced the risk of type 2 diabetes across all trials by 11% (hazard ratio 0·89 [95% CI 0·84-0·95]). Investigation of the effects of five major classes of antihypertensive drugs showed that in comparison to placebo, angiotensin-converting enzyme inhibitors (RR 0·84 [95% 0·76-0·93]) and angiotensin II receptor blockers (RR 0·84 [0·76-0·92]) reduced the risk of new-onset type 2 diabetes; however, the use of β blockers (RR 1·48 [1·27-1·72]) and thiazide diuretics (RR 1·20 [1·07-1·35]) increased this risk, and no material effect was found for calcium channel blockers (RR 1·02 [0·92-1·13]).

Interpretation

Blood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes. Established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes. This evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes.

Funding

British Heart Foundation, National Institute for Health Research, and Oxford Martin School.

Sources & attribution

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, Smith Byrne K, Sundström J, Teo K, Davis BR, Chalmers J, Pepine CJ, Dehghan A, Bennett DA, Smith GD, Rahimi K, Blood Pressure Lowering Treatment Trialists’ Collaboration.

Lancet (London, England) · 2021-11-01

DOI: 10.1016/s0140-6736(21)01920-6 ↗PubMed · 34774144 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Observational meta-analysis

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

In-depth explainersRead study →
·Trial meta-analysis

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

In-depth explainersRead study →
·Randomised trial

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

In-depth explainersRead study →
·Validation study/review

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

In-depth explainersRead study →
Cardiovascular health →